Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1Phase 1/2 1

Status

Unknown 3Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Thoracic 3Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Neoplasm Metastasis 2Uterine Cervical Neoplasms 1Sarcoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Polycystic Ovary Syndrome 1Neoplasms 1Melanoma 1Lymphoma 1Leukemia, Lymphocytic, Chronic, B-Cell 1Drug-Related Side Effects and Adverse Reactions 1Colorectal Adenocarcinoma 1Carcinoma, Hepatocellular 1Adenomatous Polyposis Coli 1

Interventions

Carboplatin 84Cisplatin 79Pemetrexed 72Docetaxel 62Drug Therapy 44Gemcitabine 43Erlotinib Hydrochloride 42Gefitinib 38Radiotherapy 36Paclitaxel 36pembrolizumab 31Bevacizumab 29icotinib 28osimertinib 27anlotinib 26Nivolumab 26camrelizumab 23Vinorelbine 23Radiosurgery 20aumolertinib 18atezolizumab 17sintilimab 16apatinib 16Endostatins 16endostar protein 15durvalumab 14Surgical Procedures, Operative 13Immunotherapy 13Immune Checkpoint Inhibitors 12Blood Specimen Collection 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Unknown × Carcinoma, Non-Small-Cell Lung × Pharmaceutical Preparations × Clear all
NCT03489616 2018-04-05

CRAGMOLC

Shandong Cancer Hospital and Institute

Phase NA Unknown
45 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT01027676 2013-11-14

Study of Vorinostat and Gefitinib in Relapsed/ or Refractory Patients With Advanced Non-small Cell Carcinoma (NSCLC)

National Cancer Center, Korea

Phase 1/2 Unknown
50 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT00285675 2006-05-31

Study of DN-101 (Calcitriol) and Docetaxel in Subjects Previously Enrolled in Studies DN101-002 or DN101-004

Novacea

Phase 2 Unknown
25 enrolled
GenitourinaryThoracic

Carcinoma, Non-Small-Cell Lung, Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡